Dilek Turgut-Balik

Dilek Turgut-Balik

Auto-generated profile, based on publicly available information

Dilek Turgut-Balik

Department of Bioengineering, Faculty of Chemical and Metallurgical Engineering, Yıldız Technical University, İstanbul, Turkey

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2020 in TURKISH JOURNAL OF BIOLOGY
Verified
Journal Article
Open access
OUOsman Mutluhan Ugurel
Osman Mutluhan Ugurel
OAOguz Ata
Oguz Ata
DTDilek Turgut-Balik
Dilek Turgut-Balik
A novel pathogen, named SARS-CoV-2, has caused an unprecedented worldwide pandemic in the first half of 2020. As the SARS-CoV-2 genome sequences have become available, one of the important focus of scientists has become tracking variations in the viral genome. In this study, 30366 SARS-CoV-2 isolate genomes were aligned using the software developed by our group (ODOTool) and 11 variations in SARS-CoV-2 genome over 10% of whole isolates were discussed. Results indicated that, frequency rates of these 11 variations change between 3.56%–88.44 % and these rates differ greatly depending on the continents they have been reported. Despite some variations being in low frequency rate in some continents, C14408T and A23403G variations on Nsp12 and S protein, respectively, observed to be the most prominent variations all over the world, in general, and both cause missense mutations. It is also notable that most of isolates carry C14408T and A23403 variations simultaneously and also nearly all isolates carrying the G25563T variation on ORF3a, also carry C14408T and A23403 variations, although their location distributions are not similar. All these data should be considered towards development of vaccine and antiviral treatment strategies as well as tracing diversity of virus in all over the world.

21 June 2020 in TURKISH JOURNAL OF BIOLOGY
Verified
Journal Article
Open access
MTMurat Topuzogullari
Murat Topuzogullari
TATayfun ACAR
Tayfun ACAR
PAPELIN PELIT ARAYICI
PELIN PELIT ARAYICI
BUBurcu Uçar
Burcu Uçar
EUErennur Uğurel
Erennur Uğurel
SASerap ACAR
Serap ACAR
SARS-CoV-2 is a new member of the coronavirus family and caused the pandemic of coronavirus disease 2019 (COVID-19) in 2020. It is crucial to design and produce an effective vaccine for the prevention of rapid transmission and possible deaths wcaused by the disease. Although intensive work and research are being carried out all over the world to develop a vaccine, an effective and approved formulation that can prevent the infection and limit the outbreak has not been announced yet. Among all types of vaccines, epitope-based peptide vaccines outshine with their low-cost production, easy modification in the structure, and safety. In this review, vaccine studies against COVID-19 have been summarized and detailed information about the epitope-based peptide vaccines against COVID-19 has been provided. We have not only compared the peptide vaccine with other types of vaccines but also presented comprehensive literature information about development steps for an effective and protective formulation to give an insight into on-going peptide vaccine studies against SARS-CoV-2.

16 September 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
OMOzal Mutlu
Ozal Mutlu
OUOsman Mutluhan Ugurel
Osman Mutluhan Ugurel
ESEmrah Sariyer
Emrah Sariyer
OAOguz Ata
Oguz Ata
TITugba Gul Inci
Tugba Gul Inci
DTDilek Turgut-Balik
Dilek Turgut-Balik
In this study, the Nsp12–Nsp8 complex of SARS-CoV-2 was targeted with structure-based and computer-aided drug design approach because of its vital role in viral replication. Sequence analysis of RNA-dependent RNA polymerase (Nsp12) sequences from 30,366 different isolates were analysed for possible mutations. FDA-approved and investigational drugs were screened for interaction with both mutant and wild-type Nsp12–Nsp8 interfaces. Sequence analysis revealed that 70.42% of Nsp12 sequences showed conserved P323L mutation, located in the Nsp8 binding cleft. Compounds were screened for interface interaction, any with XP GScores lower than −7.0 kcal/mol were considered as possible interface inhibitors. RX-3117 (fluorocyclopentenyl cytosine) and Nebivolol had the highest binding affinities in both mutant and wild-type enzymes, therefore they were selected and resultant protein–ligand complexes were simulated for analysis of stability over 100 ns. Although the selected ligands had partial mobility in the binding cavity, they were not removed from the binding pocket after 100 ns. The ligand RX-3117 remained in the same position in the binding pocket of the mutant and wild-type enzyme after 100 ns MD simulation. However, the ligand Nebivolol folded and embedded in the binding pocket of mutant Nsp12 protein. Overall, FDA-approved and investigational drugs are able to bind to the Nsp12–Nsp8 interaction interface and prevent the formation of the Nsp12–Nsp8 complex. Interruption of viral replication by drugs proposed in this study should be further tested to pave the way for in vivo studies towards the treatment of COVID-19. Communicated by Ramaswamy H. Sarma

25 March 2014 in Molecular Biotechnology
Verified
Journal Article
Closed access
PDF file
ECEbru Cayir
Ebru Cayir
AEAysegul Erdemir
Aysegul Erdemir
EOEbru Ozkan
Ebru Ozkan
MTMurat Topuzogullari
Murat Topuzogullari
ZBZeynep Busra Bolat
Zeynep Busra Bolat
DTDilek Turgut-Balik
Dilek Turgut-Balik


26 February 2016 in Molecular Biotechnology
Verified
Journal Article
Closed access
PDF file
BYBelma Nural Yaman
Belma Nural Yaman
AEAysegul Erdemir
Aysegul Erdemir
OMOzal Mutlu
Ozal Mutlu
SYSinem Yakarsonmez
Sinem Yakarsonmez
ODOzkan Danis
Ozkan Danis
DTDilek Turgut-Balik
Dilek Turgut-Balik